You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Milhem M, Zakharia Y, Davar D, et al
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0304